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ABSTRACT
Introduction: Dipeptidyl peptidase-4 (DPP-4)
inhibitors reduce blood glucose in a dose-de-
pendent manner, but the dose-dependent effect
relationship between DPP-4 inhibitors and
atherosclerosis has not been investigated.
Methods: Patients with type 2 diabetes mellitus
(T2DM) treated with insulin were randomized
to the sitagliptin (n = 137) or conventional
treatment group (n = 137). In the sitagliptin
group, each investigator was allowed to adjust
the sitagliptin dose to avoid hypoglycemia. In
this post hoc analysis, subjects in the sitagliptin
group were divided into two groups based on
the average dose of sitagliptin during the study
period: greater than or equal to median (higher
sitagliptin dose group) or less than median
(lower sitagliptin dose group).
Results: In this study, subjects were divided
into three groups: the conventional treatment
group (n = 137), lower sitagliptin dose group
(n = 42), and higher sitagliptin dose group
(n = 95). The higher sitagliptin dose group had a
significantly larger reduction in HbA1c
(-0.62 ± 1.05%) than the conventional treat-
ment group (-0.20 ± 0.91%, P = 0.007). Over
104 weeks, the higher sitagliptin dose signifi-
cantly reduced the mean intima media thick-
ness-common carotid artery (IMT-CCA) and left
max-IMT-CCA relative to baseline. In addition,
the higher sitagliptin dose significantly inhib-
ited the progression in mean-IMT-CCA com-
pared with conventional treatment. Multiple
linear regression analysis showed that changesEnhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
074CF06070B4D456.
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in mean-IMT-CCA and left max-IMT-CCA
decreased with higher sitagliptin dose.
Conclusions: Addition of sitagliptin to insulin
therapy might attenuate the progression of
atherosclerosis in patients with T2DM in a
dose-dependent manner.
Funding: Mitsubishi Tanabe Pharma Co., Ono
Pharmaceutical Co., and Novo Nordisk.
Clinical trial registration: UMIN000007396
Keywords: Carotid atherosclerosis;
Dose-dependent effect; Sitagliptin; Type 2
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a strong risk
factor for cardiovascular disease (CVD). One of
themain goals in T2DMmanagement is to reduce
the incidence of CVD through glycemic control
and modification of risk factors for atherosclerosis
[1]. To achieve this goal, it is important to choose
oral hypoglycemic agents (OHAs) that can slow
down the progression of atherosclerosis.
Carotid artery intima media thickness (IMT)
and its progression as evaluated by ultrasonog-
raphy are well-established markers of
atherosclerosis [2–4]. To evaluate the effect of
dipeptidyl peptidase-4 (DPP-4) inhibitors on
IMT, we previously conducted the Sitagliptin
Preventive Study of Intima-Media Thickness
Evaluation (SPIKE). In this study, we demon-
strated that sitagliptin attenuates the progres-
sion of carotid IMT in patients with T2DM
treated with insulin without increasing the risk
of hypoglycemia and weight gain compared to
patients who received conventional therapy [5].
After DPP-4 inhibitors were launched on the
market in Japan in 2009, frequent hypo-
glycemic events were reported, especially in
elderly patients with renal dysfunction treated
with high-dose sulfonylureas in routine clinical
settings [6]. Taking these adverse effects of
DPP-4 inhibitors into consideration, the Japan
Association for Diabetes and Education Care
committee on adequate use of incretin-based
therapy released a warning that the dose of
insulin should be reduced when it is used in
combination with DPP-4 inhibitors [7]. In
response to this recommendation, in the SPIKE
study we left the starting dose of sitagliptin to
each investigator’s discretion when it was used
with insulin to avoid the risk of hypoglycemia.
As a result, the dose of sitagliptin varied among
patients in the sitagliptin treatment group even
though sitagliptin improved glycemic control
in a dose-dependent manner [8]. In addition to
its dose-dependent glucose-lowering effect,
sitagliptin was associated with a dose-depen-
dent reduction of the intima-media ratio in an
obese rat model of diabetes [9]. Nevertheless, we
have not yet considered whether the dose of
sitagliptin affects the progression of atheroscle-
rosis. Thus, the aim of this post hoc analysis is
to investigate the dose-dependent effect of
sitagliptin on the progression of atherosclerosis.
METHODS
Study Population
We conducted a post hoc analysis of the SPIKE
study, whose methods were described in detail
previously [5, 10–14]. Briefly, a total of 282
Japanese patients with T2DM treated with
insulin and no past history of apparent CVD
were randomly allocated to either the sitaglip-
tin group (n = 142) or the conventional treat-
ment group (n = 140). Randomization was
performed using a dynamic allocation method
based on age, gender, number of insulin injec-
tions daily, and concurrent pioglitazone use.
Patients in the sitagliptin group were started on
sitagliptin at 25 mg once daily in addition to
ongoing insulin therapy. Initiation of sitaglip-
tin at 50 mg once daily was permitted in
patients not on any sulfonylureas. After
12 weeks of treatment with sitagliptin at 25 or
50 mg, the dose of sitagliptin was scheduled to
increase to a maximum of 100 mg once daily if
HbA1c was C7.0% (8.6 mmol/l) [15]. However,
participating physicians were allowed to reduce
sitagliptin to 25 or 50 mg/day if treatment with
50 or 100 mg/day was considered to be poorly
tolerated. Insulin dose adjustment was also
permitted. In the conventional treatment
group, either increasing the dose of current
therapy (e.g., insulin) or the addition of OHAs
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was allowed to achieve optimal glycemic con-
trol [15]. The addition of other DPP-4 inhibitors
and glucagon-like peptide-1 (GLP-1) analogs
was not allowed in either group. All patients
who agreed to participate provided written
informed consent before being enrolled into the
study. The SPIKE study was registered with the
University Hospital Medical Information Net-
work Clinical Trials Registry (UMIN000007396)
and met the requirements of the International
Committee of Medical Journal Editors.
Compliance with Ethical Guidelines
The study protocol was approved by the insti-
tutional review board of each participating
institutionand complies with the current legal
regulations in Japan. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human experi-
mentation (institutional and national) and with
the Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
Measurement of Carotid IMT
Each participant underwent ultrasonography of
the carotid arteries by expert sonographers at
the start of the study [5, 10]. All scans were
electronically stored and emailed to the IMT
Evaluation Committee (Osaka, Japan), where a
single experienced reader blinded to the clinical
characteristics of the patients interpreted them
using automated digital edge-detection software
(Intimascope; MediaCross, Tokyo, Japan). The
software system evaluates an average of
approximately 200 IMT values in a segment
2 cm proximal to the dilation of the carotid
bulb (mean-IMT-CCA). Maximum IMT, includ-
ing plaque lesions in the common carotid
arteries (max-IMT-CCA), were measured
separately.
Statistical Analysis
Results are presented as mean ± SD, medians
(interquartile range), or number (proportion) of
patients. Patients in the sitagliptin group were
further classified into two subgroups based on
whether their average dose of sitagliptin during
the study period was greater than or equal to
the median dose (higher sitagliptin dose group)
or less than the median dose (lower sitagliptin
dose group). We analyzed the differences
between these two groups and the conventional
group. Baseline and follow-up group compar-
isons were assessed using analysis of variance
(ANOVA) for continuous variables and Fisher’s
exact test for categorical variables. Changes
from baseline to 104 weeks were analyzed using
a one-sample t test within each group. Differ-
ences in delta change in clinical parameters
from baseline to 104 weeks among groups were
analyzed with ANOVA followed by the
Tukey-Kramer test. Differences in delta change
in IMT from baseline to 104 weeks among
groups were analyzed with analysis of covari-
ance (ANCOVA) followed by the Tukey-Kramer
test.
Trends in the change in IMT across the three
groups were evaluated using linear regression
analysis with an unadjusted model that inclu-
ded only the treatment group (henceforth,
model 1) and the following models: model 2
(model 1 ? age, gender, and baseline IMT),
model 3 (model 2 ? HbA1c at baseline, sul-
fonylurea use, and glinide use), and model 4
(model 3 ? change in HbA1c from baseline to
104 weeks).
All statistical tests were two-sided with a
significance level of 5%. All analyses were per-
formed using SAS software version 9.4 (SAS
Institute, Cary, NC, USA).
RESULTS
Results from the Original SPIKE Study
Among a total of 282 participants, 137 in the
sitagliptin group and 137 in the conventional
treatment group were included in the full
analysis set for the original study. Baseline
clinical characteristics were comparable
between the groups as previously described [5].
In the original study, patients who received
sitagliptin had significantly greater reductions
in mean-IMT-CCA and left max-IMT-CCA but
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not right max-IMT-CCA than patients receiving
conventional treatment [5].
Baseline Characteristics
In this post hoc analysis, subjects were divided
into three groups: the conventional treatment
group (n= 137), lower sitagliptin dose group
(n= 42; average dose about 5 mg n= 1,
about10 mg n= 2, about 15 mg n= 1, about
20 mg n= 3, about 25 mg n= 18, about 40 mg
n= 7, about 45 mg n= 10), and higher sitagliptin
dose group (n= 95; average dose about 50 mg
n= 54, about 55 mg n= 3, about 60 mg n= 1,
about 65 mg n= 1, about 70 mg n= 4, about
75 mg n= 4, about 80 mg n= 5, about 85 mg
n= 5, about 90 mg n= 18). The mean dose of
sitagliptin was 53.2 mg/day (median 50 mg/day)
among patients who received sitagliptin in the
original study. The mean dose in the higher sita-
gliptin dose group was 63.3 mg/day, and the
mean dose in the lower sitagliptin dose group was
30.5 mg/day. Demographic and baseline charac-
teristics of the three groups were well balanced
except for HbA1c, sulfonylurea use, and glinide
use (Table 1). During the study, five patients
developed CVD (the conventional treatment
group, n= 2; lower sitagliptin dose group, n= 1;
higher sitagliptin dose group, n= 2, P= 0.85).
Changes in Clinical Parameters
in the Three Groups
Although higher sitagliptin dose and conven-
tional treatment both significantly reduced
HbA1c levels from baseline, the improvement
in HbA1c was significantly greater in the higher
sitagliptin dose group (-0.62 ± 1.05%) than in
the conventional treatment group
(-0.20 ± 0.91%, P = 0.007), but not than the
lower sitagliptin dose group (Table 2). On the
other hand, body mass index, blood pressure,
lipid parameters, and renal function were not
significantly different among the three groups
during the observation period (Table 2). With
respect to hypoglycemic events, there was a
significant difference in the mean number of
events among the three groups (0.36 ± 0.80
episodes/month/person in the conventional
treatment group, 0.67 ± 1.28 in the lower sita-
gliptin dose group, and 0.20 ± 0.52 in the
higher sitagliptin dose group, P = 0.008 by
ANOVA). On average, patients in the higher
sitagliptin dose group had fewer hypoglycemic
events than patients in the lower sitagliptin
dose group (P = 0.006 by Tukey-Kramer test).
Changes in IMT-CCA Among the Three
Groups
Over 104 weeks, a higher sitagliptin dose was
associated with reduced mean-IMT-CCA and
left max-IMT-CCA relative to baseline (Table 3),
but not a lower sitagliptin dose or conventional
treatment. In an ANOVA model that adjusted
for group, age, gender, and IMT values at base-
line, a higher sitagliptin dose significantly pre-
vented progression of mean-IMT-CCA and
tended to prevent progression of left max-
IMT-CCA when compared with conventional
treatment (Table 4).
Furthermore, we investigated the dose-de-
pendent effect of sitagliptin on the progression
of atherosclerosis. Linear regression analysis
showed a negative linear trend between treat-
ment group and changes in IMT-CCA and left
max-IMT-CCA, but not right max-IMT-CCA, in
the unadjusted model (model 1) and adjusted
models (models 2–4) (Table 5). Similarly, there
was a negative linear trend between the average
dose of sitagliptin over 104 weeks (the dose of
sitagliptin in the conventional treatment group
was defined as 0 mg) and changes in IMT-CCA
and left max-IMT-CCA, but not right max-
IMT-CCA (Table 6).
DISCUSSION
In this post hoc study, sitagliptin as an addition
to insulin therapy attenuated the progression of
atherosclerosis in patients with T2DM in a
dose-dependent manner. Thus, this finding
lends support to the conclusion that this
anti-atherosclerotic effect was due to the drug
effect of sitagliptin itself.
A previous study demonstrated that sita-
gliptin inhibited plasma DPP-4 activity over
24 h and increased active GLP-1 levels in a
1138 Diabetes Ther (2017) 8:1135–1146
Table 1 Baseline clinical characteristics of patients by treatment group
Parameters Conventional
treatment group
Lower sitagliptin
dose group
(<50 mg/day)
Higher sitagliptin
dose group
(‡50 mg/day)
P value
(intergroup)
Age (years) 63.6 ± 10.0 (n = 137) 65.3 ± 9.9 (n = 42) 63.2 ± 9.6 (n = 95) 0.51
Male gender 82 (59.9%) 27 (64.3%) 56 (58.9%) 0.84
Duration of diabetes (years) 17.3 ± 8.7 (n = 134) 17.6 ± 8.7 (n = 41) 17.1 ± 8.4 (n = 94) 0.96
Body mass index (kg/m2) 25.1 ± 3.4 (n = 137) 24.6 ± 4.2 (n = 42) 25.2 ± 4.4 (n = 95) 0.74
HbA1c (%) 8.0 ± 1.0 (n = 137) 7.7 ± 0.8 (n = 42) 8.3 ± 1.1 (n = 95) 0.002
HbA1c (mmol/mol) 63.9 ± 10.6 (n = 137) 60.0 ± 8.8 (n = 42) 67.1 ± 12.5 (n = 95) 0.002
Total cholesterol (mmol/l) 4.94 ± 0.86 (n = 137) 4.86 ± 0.73 (n = 41) 5.08 ± 0.98 (n = 95) 0.32
LDL cholesterol (mmol/l) 2.78 ± 0.70 (n = 136) 2.84 ± 0.58 (n = 42) 2.85 ± 0.85 (n = 95) 0.74
HDL cholesterol (mmol/l) 1.39 ± 0.38 (n = 136) 1.41 ± 0.40 (n = 42) 1.48 ± 0.36 (n = 95) 0.23
Triglycerides (mmol/l) 1.17 (0.90, 1.72)
(n = 137)
1.16 (0.89, 1.40)
(n = 42)
1.11 (0.79, 1.67)
(n = 94)
0.76
Systolic BP (mmHg) 132.0 ± 14.3
(n = 137)
130.6 ± 16.5
(n = 42)
130.0 ± 15.5 (n = 95) 0.60
Diastolic BP (mmHg) 74.7 ± 12.0 (n = 137) 76.8 ± 10.9 (n = 42) 74.3 ± 11.1 (n = 95) 0.48
eGFR (ml/min/1.73 m2) 79.7 ± 24.2 (n = 137) 75.4 ± 17.9 (n = 42) 78.7 ± 22.5 (n = 95) 0.56
UAE (mg/g creatinine) 108.9 ± 224.3
(n = 134)
83.4 ± 173.9
(n = 42)
226.6 ± 666.6
(n = 94)
0.08
Number of insulin injections
(times/day)
2.9 ± 1.2 (n = 137) 3.1 ± 1.0 (n = 42) 2.8 ± 1.2 (n = 95) 0.64
Metformin 48 (35.0) 13 (31.0) 36 (37.9) 0.73
Sulfonylurea 15 (10.9) 13 (31.0) 4 (4.2) \0.001
Glinide 19 (13.9) 0 (0) 2 (2.1) \0.001
Thiazolidinedione 11 (8.0) 4 (9.5) 9 (9.5) 0.88
a-Glucosidase inhibitor 42 (30.7) 11 (26.2) 30 (31.6) 0.82
Angiotensin-converting
enzyme inhibitor
4 (2.9) 3 (7.1) 5 (5.3) 0.40
Angiotensin II receptor
blocker
69 (50.4) 17 (40.5) 36 (37.9) 0.15
Statin 63 (46.0) 21 (50.0) 45 (47.4) 0.89
Antiplatelet agent 30 (21.9) 12 (28.6) 17 (17.9) 0.36
Data are number (%) of patients, mean ± SD, or medians (range)
Differences in parameters among groups were analyzed by analysis of variance or Fisher’s exact test
BP blood pressure, eGFR estimated glomerular ﬁltration rate, UAE urinary albumin excretion
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dose-dependent manner after an oral glucose
tolerance test, but there was no difference in
effect on glucose excursion after an oral glucose
tolerance test between a single oral 25- or
200-mg dose of sitagliptin [16]. On the other
hand, sitagliptin reduced HbA1c in a dose-de-
pendent manner over 12 weeks in a longer-term
study [8]. In that study, the addition of sita-
gliptin to insulin therapy nearly
dose-dependently reduced HbA1c levels over
104 weeks. From this point of view, one might
expect that a higher dose of sitagliptin can sig-
nificantly reduce carotid atherosclerosis
through its glucose-lowering effects. In fact, a
higher sitagliptin dose attenuated the progres-
sion of carotid atherosclerosis along with
reducing HbA1c levels. However, sitagliptin
treatment still attenuated the progression of
Table 2 Changes in clinical parameters from baseline to 104 weeks and frequency of hypoglycemic events
Parameters Conventional
treatment group
Lower sitagliptin
dose group
Higher sitagliptin
dose group
P value
(intergroup)
Body mass index (kg/m2) 0.12 ± 1.77
(n = 117)
0.04 ± 1.15
(n = 37)
0.08 ± 1.62
(n = 82)
0.96
HbA1c (%) -0.20 ± 0.91
(n = 122)*
-0.25 ± 0.97
(n = 37)
-0.62 ± 1.05
(n = 84)§
0.008
HbA1c (mmol/mol) -2.23 ± 9.99
(n = 122)*
-2.72 ± 10.61
(n = 37)
-6.82 ± 11.52
(n = 84)§
0.008
Total cholesterol (%) -1.79 ± 14.60
(n = 122)
1.16 ± 13.55
(n = 37)
-4.44 ± 16.16
(n = 84)*
0.15
LDL cholesterol (%) 5.18 ± 23.93
(n = 121)*
3.39 ± 23.90
(n = 38)
-0.20 ± 23.29
(n = 84)
0.28
HDL cholesterol (%) -0.46 ± 14.72
(n = 121)
4.53 ± 16.21
(n = 37)
-1.74 ± 14.49
(n = 84)
0.10
Triglycerides (%) -1.58 (-24.57,
16.67) (n = 122)
-1.89 (-28.57,
49.06) (n = 37)
0.00 (-24.22,
43.75) (n = 83)*
0.29
Systolic BP (mmHg) 2.52 ± 16.75
(n = 122)
1.83 ± 18.71
(n = 36)
-1.45 ± 19.11
(n = 83)
0.29
Diastolic BP (mmHg) 2.19 ± 13.15
(n = 122)
-1.00 ± 12.94
(n = 36)
0.42 ± 10.05
(n = 83)
0.32
eGFR (ml/min/1.73 m2) -2.65 ± 11.76
(n = 122)*
-4.56 ± 8.69
(n = 36)#
-3.70 ± 11.00
(n = 84)#
0.61
UAE (mg/g creatinine) 23.9 ± 249.6
(n = 114)
63.2 ± 222.3
(n = 35)
-18.9 ± 356.4
(n = 79)
0.34
Frequency of hypoglycemic events
(episodes/month/person)
0.36 ± 0.80 0.67 ± 1.28 0.20 ± 0.52 0.008
Data are mean ± SD, medians (interquartile range), or values
Differences in parameters from baseline to 104 weeks among groups were analyzed using analysis of variance
Changes from baseline to 104 weeks within a group were analyzed using a one-sample t test
BP blood pressure, eGFR estimated glomerular ﬁltration rate, UAE urinary albumin excretion
*P\0.05, #P\0.01, §P\0.001
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mean-IMT-CCA and left max-IMT-CCA in a
dose-dependent manner even after adjusting for
changes in HbA1c from baseline. This suggests
that sitagliptin treatment attenuated the pro-
gression of carotid artery atherosclerosis in a
dose-dependent manner independent of its
glucose-lowering effects.
The exact mechanism by which sitagliptin
attenuates the progression of carotid IMT
remains unclear in this post hoc analysis. One
possibility is that sitagliptin slowed it down by
enhancing GLP-1 signaling; a previous study
demonstrated that sitagliptin increased GLP-1
activity in a dose-dependent manner after an
oral glucose tolerance test [16]. In fact, des-flu-
oro-sitagliptin was reported to inhibit macro-
phage inflammation through enhancement of
GLP-1 signaling in a dose-dependent manner in
an in vitro study [17]. Another possibility is that
DPP-4 inhibitors have the potential to inhibit
the progression of atherosclerosis in a
GLP-1–independent manner. DPP-4 inhibitors
have various functions in vascular cells. In a rat
model of diabetes [9], sitagliptin reduced
neointimal formation after carotid injury in a
dose-dependent manner. In the same study,
sitagliptin inhibited smooth muscle cell prolif-
eration and monocyte adhesion in a dose-de-
pendent manner independent of GLP-1 activity
in vitro. Consistent with these findings, we
previously demonstrated that anagliptin,
another DPP-4 inhibitor, suppresses smooth
muscle cell proliferation and reduces macro-
phage inflammation almost in a dose-depen-
dent manner [18]. Taken together, the
anti-atherosclerotic effect of DPP-4 inhibitors
may be independent of their glycemic effects in
a dose-dependent manner; however, it is
unclear whether the effects are mediated by
GLP-1.
In this post hoc analysis, some investigators
probably used lower doses of sitagliptin because
of concerns about hypoglycemia when sita-
gliptin is used as an adjunct to insulin therapy.
Unexpectedly, the number of hypoglycemic
events was significantly higher in the lower
sitagliptin dose group than in the higher sita-
gliptin dose treatment group. This may be
Table 3 IMT values at baseline and 104 weeks by treatment group
Parameter Conventional treatment
group
Lower sitagliptin dose
group
Higher sitagliptin dose
group
P value
(intergroup)
Mean IMT-CCA (mm)
Baseline (mm) 0.84 ± 0.21 (n = 137) 0.82 ± 0.21 (n = 42) 0.85 ± 0.17 (n = 95) 0.69
104 weeks (mm) 0.86 ± 0.24 (n = 122) 0.83 ± 0.24 (n = 38) 0.81 ± 0.17 (n = 83) 0.16
P value (intragroup) 0.06 0.61 0.001
Right maximum IMT-CCA (mm)
Baseline (mm) 1.06 ± 0.40 (n = 137) 1.05 ± 0.30 (n = 41) 1.04 ± 0.28 (n = 95) 0.91
104 week (mm) 1.09 ± 0.49 (n = 122) 1.11 ± 0.41 (n = 38) 1.00 ± 0.30 (n = 83) 0.26
P value (intragroup) 0.51 0.44 0.51
Left maximum IMT-CCA (mm)
Baseline (mm) 1.11 ± 0.41 (n = 137) 1.06 ± 0.34 (n = 42) 1.12 ± 0.32 (n = 95) 0.64
104 week (mm) 1.12 ± 0.42 (n = 122) 1.04 ± 0.32 (n = 38) 1.03 ± 0.29 (n = 83) 0.19
P value (intragroup) 0.39 0.88 0.010
Data are mean ± SD. Differences in parameters among groups were analyzed using analysis of variance
Differences in parameters from baseline to 104 weeks within a group were analyzed using a one-sample t test
CCA common carotid artery, IMT intima-media thickness
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associated with imbalances in sulfonylurea use
among groups. In other words, add-on sitaglip-
tin therapy increased the number of hypo-
glycemic events in patients on insulin and
sulfonylurea combination therapy even though
healthcare providers lowered the dose of sita-
gliptin. More episodes of hypoglycemia may
reduce the beneficial effect of sitagliptin on the
changes in carotid IMT. Indeed, we previously
demonstrated that a higher frequency of hypo-
glycemia is associated with increases in carotid
IMT [14]. Thus, we should take precautions
against potential hypoglycemia when DPP-4
inhibitors are added to insulin and sulfonylurea
combination therapy. On the other hand, a
higher sitagliptin dose attenuated the progres-
sion of carotid IMT without increasing the
number of hypoglycemic events. Thus, we may
consider using a higher dose of DPP-4 inhibitors
from the perspective of preventing the pro-
gression of atherosclerosis while reducing the
dose of insulin or reducing or discontinuing
sulfonylurea therapy.
The present study has certain limitations.
First, because this was an exploratory post hoc
analysis of a randomized open-label trial, the
findings may be limited. In particular, the clas-
sification of subgroups based on the average
dose of sitagliptin may cause selection bias that
interferes the results although we conducted
the analysis adjusting for an imbalance in
baseline characteristics among groups. Second,
because these were exploratory analyses, the
issue of multiple statistical comparisons
becomes a concern, and findings should be
interpreted with caution. Third, the carotid IMT
results were not completely consistent,
although the results tended to show a similar
Table 4 Changes in intima-media thickness among groups
Parameters Treatment effect
(mm)
P value by
ANCOVA
P value by
Tukey-Kramer
Mean IMT-CCA (mm)
Conventional treatment group vs. lower sitagliptin dose group -0.02 (-0.08, 0.05) 0.006 0.82
Conventional treatment group vs. higher sitagliptin dose group -0.07 (-0.12, -0.02) 0.004
Lower sitagliptin dose group vs. higher sitagliptin dose group -0.05 (-0.12, 0.02) 0.19
Right maximum IMT-CCA (mm)
Conventional treatment group vs. lower sitagliptin dose group 0.02 (-0.13, 0.17) 0.43 0.95
Conventional treatment group vs. higher sitagliptin dose group -0.05 (-0.17, 0.06) 0.51
Lower sitagliptin dose group vs. higher sitagliptin dose group -0.08 (-0.24, 0.09) 0.52
Left maximum IMT-CCA (mm)
Conventional treatment group vs. lower sitagliptin dose group -0.06 (-0.19, 0.07) 0.06 0.51
Conventional treatment group vs. higher sitagliptin dose group -0.10 (-0.19, 0.00) 0.05
Lower sitagliptin dose group vs. higher sitagliptin dose group -0.04 (-0.17, 0.10) 0.79
Data are mean differences (95% conﬁdence interval)
Differences in delta change in IMT from baseline to 104 weeks among groups (treatment effect) were analyzed with analysis
of covariance after adjustment for baseline IMT, age, and gender followed by the Tukey-Kramer test
Treatment effect = (Delta change in IMT from baseline to 104 weeks in the lower sitagliptin dose group) - (delta change
in IMT from baseline 104 weeks in the conventional treatment group), (delta change in IMT from baseline 104 weeks in
the higher sitagliptin dose) - (delta change in IMT from baseline 104 weeks in the conventional treatment group), or (delta
change in IMT from baseline 104 weeks in the higher sitagliptin dose group) - (delta change in IMT from baseline
104 weeks in the lower sitagliptin dose group)
CCA common carotid artery, IMT intima-media thickness
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pattern. These differences may be associated
with the underpowered sample and differences
in carotid IMT by laterality [19]. Fourth, the
evaluation of average IMT by 0.01 mm may be
difficult for non-experts in clinical practice
although this method is well established and
widely used in clinical studies. Fifth, we used
surrogate markers for CVD as the primary end-
point. The reduction of IMT with sitagliptin
treatment may be expected to be associated
with a reduction in the onset of CVD consid-
ering the results of a meta-analysis showing that
DPP-4 inhibitors have the potential to reduce
the onset of CVD [20]. However, our study
lacked sufficient power to detect differences in
the onset of CVD. Finally, the number of
patients in the lower sitagliptin dose group was
small.
CONCLUSIONS
Our data suggest that sitagliptin treatment is
effective in attenuating the progression of car-
otid atherosclerosis in a dose-dependent man-
ner in patients with T2DM on insulin therapy.
Table 5 Trends between sitagliptin dose when classiﬁed
into three groups and change in IMT
Variable Regression coefﬁcient (SE) P value
Change in mean IMT-CCA
Model 1 -0.0015 (0.0004) \0.001
Model 2 -0.0013 (0.0004) 0.002
Model 3 -0.0014 (0.0004) \0.001
Model 4 -0.0014 (0.0004) 0.002
Change in right max IMT-CCA
Model 1 -0.0008 (0.0010) 0.42
Model 2 -0.0010 (0.0010) 0.29
Model 3 -0.0013 (0.0010) 0.20
Model 4 -0.0012 (0.0010) 0.25
Change in left max IMT-CCA
Model 1 -0.0022 (0.0009) 0.014
Model 2 -0.0019 (0.0008) 0.018
Model 3 -0.0023 (0.0008) 0.006
Model 4 -0.0023 (0.0009) 0.008
Estimation of a linear trend across sitagliptin dose, deﬁned
as the conventional treatment group, lower sitagliptin dose
group, and higher sitagliptin dose group, is based on linear
regression analysis with no adjustment (Model 1), adjust-
ment for baseline IMT, age, and gender (Model 2), model
2 plus baseline HbA1c, sulfonylurea use, and glinide use
(Model 3), and model 3 plus change in HbA1c (Model 4)
CCA common carotid artery, IMT intima-media thickness
Table 6 Trend between average sitagliptin dose and
change in IMT
Variable Regression coefﬁcient (SE) P value
Change in mean IMT-CCA
Model 1 -0.0010 (0.0003) 0.003
Model 2 -0.0008 (0.0003) 0.009
Model 3 -0.0009 (0.0003) 0.006
Model 4 -0.0008 (0.0003) 0.010
Change in right max IMT-CCA
Model 1 -0.0001 (0.0008) 0.92
Model 2 -0.0002 (0.0007) 0.78
Model 3 -0.0003 (0.0008) 0.65
Model 4 -0.0002 (0.0008) 0.75
Change in left max IMT-CCA
Model 1 -0.0013 (0.0007) 0.046
Model 2 -0.0012 (0.0006) 0.06
Model 3 -0.0014 (0.0006) 0.022
Model 4 -0.0014 (0.0006) 0.030
Estimation of a linear trend across sitagliptin dose is based
on linear regression analysis with no adjustment (Model 1),
adjustment for baseline IMT, age, and gender (Model 2),
model 2 plus baseline HbA1c, sulfonylurea use, and glinide
use (Model 3), and model 3 plus change in HbA1c
(Model 4)
CCA common carotid artery, IMT intima-media thickness
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